PTO/SB/08a (05-03)

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**	TRABINA te for form 1449A/PTO	Neobel	arreter 1999, No p		omplete if Known
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number Filing Date First Named Inventor	10/716,349 November 17, 2003 BERG, ELLEN L.
Sheet	(use as many sheets as ne	cessal of	2	Art Unit Examiner Name Attorney Docket Number	1645 SEEK-001CON

Examiner Initials'		Document Number			Pages, Columns, Lines, Where
	Cite No. <sup>1</sup>	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
KRS		US-4568649	Feb., 1986	Bertoglio-Matte.	
		US- 5589588	Oct., 1996	Ashby et al.	
		US- 5831153	May., 1997	Capecchi et al.	
		US- 5777888	Jul., 1998	Rine et al.	
		US- 5994076	Nov., 1999	Chenchik et al.	
		US-6004755	Dec., 1999	Wang.	
$\mathbf{N}$		US-6013437	Jan., 2000	Luria et al.	
V		US-6146830	Nov., 2000	Friend et al.	

			FOREIG	N PATENT DO	UMENTS		
Exar	niner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials'		No.¹	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	7°
٠.			OTHER PRIOR ART. M				<u> </u>
			OTHER PRIOR ART—NO	JN PAIENI LI	ERATURE DOCUMENT	5	
Exan Initia		Cite No.1	item (book, magazine, journal, se	rial, symposium, cata	title of the article (when appropriation, etc.), date, page(s), volume		T²
K	RS		ALTSCHUL et al. (Feb. 19 Databases." Nature Geneti			lecular Sequence	
, or			BLACKSTOCK et al. (Mar. 1999), "Proteomics: Quantitative and Physical Mapping of Cellular Proteins." TIBTECH, vol. 17:121-127				
			HATZIMANIKATIS et a Experimental Consideration				
	/		HELLER et al. "Discovery genes using cDNA microa 2155, Mar. 1997				

Examiner	/Karlheinz Skowronek/	Date 10/11/2006	
Signature 1		Considered 10/11/2000	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 46 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

X Did not receive any NPL.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0551-0031

10/11/2006

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SEEK-001CON

Date

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449B/PTO **Application Number** 10/716.349 INFORMATION DISCLOSURE Filing Date November 17, 2003 STATEMENT BY APPLICANT First Named Inventor BERG, ELLEN L. Group Art Unit 1645 (use as many sheets as necessary) Examiner Name

**Attorney Docket Number** 

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*						
KRS		MULLNER et al. (1998), "Proteomincs: A New Way for Drug Target Discovery."Arzneim-Forsch., vol. 48(1):93-95				
KRS		NELLEN et al. (Nov. 1993), "What Makes an mRNA Anti-Sense-Itive?" TIBS, vol. 18:419-423				
ì						

	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.
	Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if
,	English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public
	which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120
	minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will yary depending upon the including case. Any

/Karlheinz Skowronek/

comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria; VA 22313-1450.

of

Sheet

Examiner

Signature

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

Substitute for form 1449A/PTO INFORMATION' STATEMENT BY

(use as many sheets as necessary

Sheet

Co	omplete if Known	
Application Number	10/716,349	
Filing Date	November 17, 2003	
First Named Inventor	BERG, ELLEN L.	
Art Unit	1645	
Examiner Name	<del></del>	
Attorney Docket Number	SEEK-001CON	

		FOREIG	N PATENT DO	CUMENTS		
Examiner Initials' KRS	Cite No.1	Föreign Patent Document  Country Code <sup>3</sup> —Number <sup>4</sup> —Kind Code <sup>6</sup> (if known)  WO 96/23075	Publication Date MM-DD-YYYY 08-01-1996	Name of Patentee or Applicant of Cited Document BOGGS	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
KRS	<del></del>	WO 95/06132	03-02-1995	ANDRIANOPOULOS		
VVS	<b></b>	NON PATE	NT LITERATURE	DOCUMENTS		
	Cite No. <sup>1</sup>	Include name of the author (in CAPITA magazine, journal, serial, symposium, catalo		(s), volume-issue number(s),		T
KRS		MAY et al., EFFECTS OF PROTEIN TYROSINE KINASE INHIBITORS ON CYTOKINE-INDUCED ADHESION MOLECULE EXPRESSION BY HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS, Brit. Journal, of Pharmacology, 1996, 118(7): 1761-1771				
KRS		RICE et al., DEVELOPMENT INHIBITORS OF ENDOTHEL 241(2): 254-259				
KRS	:	HAUSNER et al., THE COMPARATIVE GROWTH ASSAY: EXAMINING THE INTERPLAY OF ANTI-CANCER AGENTS WITH CELLS CARRYING SINGLE GENE ALTERATIONS, Neoplasia, Doyma, 1999, 1(4): 356-367				
Examiner	1	/Karlheinz Skowronek/	, , <del>, , , , , , , , , , , , , , , , , </del>	Date	10/11/2006	_

Signature Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent

documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols

as indicated on the document under WiPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of lime you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.